Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CPRX Hot Sheet
Price: $31.49 --0%
Financial Fact:
Loss per share - basic and diluted: -0.05
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Loss per share - basic and diluted: -0.05
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.17, $0.08 better than the analyst estimate of $0.09. Revenue for the quarter came in at $36.4 million versus the consensus estimate of $31.51 million.
For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Top restaurant stocks to watch, according to Raymond James
- RBC Capital Reiterates Outperform Rating on Verisk Analytics (VRSK)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
